Characterizing Infusion-Related Reactions in Patients with Rheumatoid Arthritis Treated with Biologic DMARDs: Observations from the KOBIO Registry

被引：0
|
作者：
Kim, Ji-Won [1 ]
Jung, Ju-Yang [1 ]
Suh, Chang-Hee [2 ]
Kim, Hyoun-Ah [1 ]
机构：
[1] Ajou Univ, Sch Med, Suwon, South Korea
[2] Ajou Univ Hosp, Suwon, South Korea
来源：
ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0517
引用
收藏
页码：1050 / 1052
页数：3
相关论文
共 50 条
  • [31] Infusion-related reactions in Black/African American and Hispanic/Latino patients treated with ocrelizumab administered as a shorter infusion
    Amjad, F.
    Okai, A.
    Obeidat, A. Z.
    Pei, J.
    Acosta, J.
    Ndrio, J.
    Magrini, F.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 586 - 586
  • [32] PREMEDICATION AND THE INCIDENCE AND SEVERITY OF INFUSION-RELATED REACTIONS IN PATIENTS TREATED WITH CETUXIMAB: DATA FROM THE CRYSTAL AND MABEL STUDIES
    Wilke, H.
    Siena, S.
    Loos, A.
    Berghoff, K.
    Koehne, C.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 71 - 72
  • [33] Uncovering risk factors for adverse events and infections in rheumatoid arthritis and rheumatoid arthritis with interstitial lung disease under treatment with biologics or targeted synthetic DMARDs: insights from the KOBIO Registry
    Kim, J.
    Shin, K.
    Jung, J.
    Suh, C.
    Lee, S.
    Kim, H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (09) : 1781 - 1791
  • [34] COSTS AND DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BIOLOGIC DMARDS: FINDINGS IN A REAL-LIFE SETTING
    Santos-Moreno, P.
    Buitrago-Garcia, D.
    Villarreal Peralta, L.
    Alvis-Zakzuk, N. J.
    Alvis-Guzman, N.
    VALUE IN HEALTH, 2019, 22 : S243 - S243
  • [35] Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry
    Lin, Ching-Tsai
    Huang, Wen-Nan
    Tsai, Wen-Chan
    Chen, Jun-Peng
    Hung, Wei-Ting
    Hsieh, Tsu-Yi
    Chen, Hsin-Hua
    Hsieh, Chia-Wei
    Lai, Kuo-Lung
    Tang, Kuo-Tung
    Tseng, Chih-Wei
    Chen, Der-Yuan
    Chen, Yi-Hsin
    Chen, Yi-Ming
    PLOS ONE, 2021, 16 (04):
  • [36] Discontinuation of DMARDs in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Blocking Agents: An Analysis in the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
    van Dartel, Sanne
    Fransen, Jaap
    Kievit, Wietske
    den Broeder, Alfons
    Visser, Henk
    Hartkamp, Andre
    van de Laar, Mart A. F.
    Van Riel, Piet
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1019 - S1020
  • [37] IMPACT OF BIOLOGIC DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS: OBSERVATION FROM THE CORRONA REGISTRY
    Pappas, D. A.
    Reed, G. W.
    Bao, Y.
    Grant, S.
    Garg, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 226 - 226
  • [38] Association between biologic disease modifying anti-rheumatic drugs and incident hypertension in patients with rheumatoid arthritis Results from prospective nationwide KOBIO Registry
    Kim, Seong-Kyu
    Kwak, Sang Gyu
    Choe, Jung-Yoon
    MEDICINE, 2020, 99 (09)
  • [39] INCREASED THROMBOEMBOLIC RISK OF JAK INHIBITORS AFTER SWITCHING FROM BIOLOGIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Eun, Y.
    Seo, G. H.
    Kang, S. Y.
    Lee, S.
    Kim, H.
    Cha, H. S.
    Koh, E. M.
    Lee, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1337 - 1337
  • [40] SEVERE INFUSION-RELATED REACTIONS ARE UNCOMMON IN RITUXUMAB-TREATED CLL PATIENTS: RESULTS FROM A NATIONAL OBSERVATIONAL STUDY
    Norin, N.
    Bjorkstrand, B.
    Rommel, F.
    Timberg, L.
    Andersson, P.
    Haggstrom, J.
    Aldrin, A.
    Hansson, L.
    HAEMATOLOGICA, 2012, 97 : 306 - 306
12345